glp 1 agonists review The expanding role of GLP-1 receptor agonists: a narrative of current evidence and future directions A clinician's perspective 📝 GLP-1

A pivotal 2021 clinical study of more than 1,900 adults, known as the STEP 1 trial, laid the groundwork for the use of these drugs as a treatment for weight loss

Ben-Shlomo S, Zvibel I, Varol C, et al

Both doses of orforglipron lowered blood sugar more than both doses of semaglutide

So in 2014, the FDA began approving these medications for weight loss first Saxenda (liraglutide) , then Wegovy (semaglutide) , Zepbound (tirzepatide) , and most recently, Foundayo (orforglipron)

Extending its duration of action has become a focus of drug development

Offers like 100 free spins promo codes spinbet require the same diligence as any other bonus